Recombinant Coagulation Factor VIII
Hemophilia A
Phase 3In Development
Key Facts
About Shanghai RAAS Blood Products
Shanghai RAAS Blood Products is a critical enterprise in China's national biopharmaceutical strategy, focusing on ensuring the supply and safety of plasma-derived therapies. The company operates numerous plasma collection stations and has a vertically integrated manufacturing platform, positioning it as a dominant force in a market with significant barriers to entry. Its strategic direction involves expanding its plasma fractionation capacity, advancing its recombinant protein pipeline, and leveraging its scale to meet growing domestic demand for essential blood products.
View full company profileTherapeutic Areas
Other Hemophilia A Drugs
| Drug | Company | Phase |
|---|---|---|
| Hemlibra (emicizumab) | Chugai Pharmaceutical | Approved |
| Factor VIII Products | CSL | Commercial |
| Gene Therapy | BioMarin Pharmaceutical | Commercial |
| Human Coagulation Factor VIII | Shanghai RAAS Blood Products | Approved |
| Factor VIII | Tiantan Bio | Approved |
| Recombinant Factor VIII | Hualan Biological Engineering | Pre-clinical |
| Giroctocogene fitelparvovec (SB-525) | Sangamo Therapeutics | Phase 3 |